← All trials
NCT06095674
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Jan 31, 2026
- Completion date
- Jan 31, 2026
- First posted
- Oct 23, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of AmsterdamLead sponsor
- Agenus Inc.Collaborator
- University of AmsterdamOverall official - principal investigator
- University of AmsterdamReponsible party - principal investigator
- Dutch Cancer SocietyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.